0000000000530693

AUTHOR

Michael Hummel

showing 2 related works from this author

Comparative characteristics of older people with type 1 diabetes treated with continuous subcutaneous insulin infusion or insulin injection therapy :…

2019

Aim To compare clinical characteristics and outcomes in adults with type 1 diabetes aged ≥ 60 years using continuous subcutaneous insulin infusion (CSII) vs. insulin injection therapy. Further, to determine the percentage of older adults with type 1 diabetes using CSII. Research design and methods Retrospective study using data of the Diabetes Prospective Follow-up Registry (DPV). Including percentage CSII use from 2008 to 2018, and the characteristics of 9547 individuals extracted from the DPV in March 2019 (N = 1404 CSII; N = 8143 insulin injection therapy). Wilcoxon rank sum tests were used for continuous variables and chi-square tests for categorical variables to compare clinical charac…

medicine.medical_specialtyDiabetic ketoacidosisEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolism03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusInternal medicineDiabetes mellitus Type 1Internal MedicineMedicine030212 general & internal medicineddc:610ContraindicationDepression (differential diagnoses)AgedType 1 diabetesbusiness.industryInsulinCSIIDiabetes mellitus; TherapyDiabetes mellitus Typ 1Retrospective cohort studymedicine.diseaseInsulin infusion systems3. Good healthMicroalbuminuriaOlder peopleInsulinpumpebusinessAlter <60-90 Jahre>
researchProduct

Synthetic lethal metabolic targeting of cellular senescence in cancer therapy.

2013

Activated oncogenes and anticancer chemotherapy induce cellular senescence, a terminal growth arrest of viable cells characterized by S-phase entry-blocking histone 3 lysine 9 trimethylation (H3K9me3). Although therapy-induced senescence (TIS) improves long-term outcomes, potentially harmful properties of senescent tumour cells make their quantitative elimination a therapeutic priority. Here we use the Eµ-myc transgenic mouse lymphoma model in which TIS depends on the H3K9 histone methyltransferase Suv39h1 to show the mechanism and therapeutic exploitation of senescence-related metabolic reprogramming in vitro and in vivo. After senescence-inducing chemotherapy, TIS-competent lymphomas but …

SenescenceMaleLymphoma B-CellTransgeneApoptosisMice TransgenicMiceUbiquitinStress PhysiologicalAutophagyAnimalsCaspase 12Cellular SenescenceMultidisciplinarybiologyCaspase 3Endoplasmic reticulumAutophagyEndoplasmic Reticulum StressSurvival RateDisease Models AnimalHistoneGlucoseBiochemistryHistone methyltransferaseProteolysisUnfolded protein responsebiology.proteinCancer researchFemaleNature
researchProduct